SPATA13: A Potential Drug Target for Neurodegenerative Diseases

Target Name: SPATA13

NCBI ID: G221178

SPATA13

SPATA13: A Potential Drug Target for Neurodegenerative Diseases

Spermatogenesis-associated protein 13 (SPATA13) is a protein that is expressed in various tissues of the body, including the testes, ovaries, and brain. It is a key regulator of spermatogonial development and has been implicated in a number of diseases, including infertility, testicular cancer, and neurodegenerative diseases.

SPATA13 is a member of the SPATA gene family, which is known for producing proteins that are involved in the regulation of cell growth, differentiation, and survival. The SPATA gene family has been identified as a potential drug target in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SPATA13 is expressed in a variety of tissues and has been shown to be involved in the regulation of spermatogonial development, including the control of meiosis I and the formation of spermatids. It has been shown to play a role in the development and maintenance of normal testicular tissue, and is implicated in the development of testicular cancer.

In addition to its role in spermatogonial development, SPATA13 is also involved in the regulation of cellular processes that are important for maintaining tissue homeostasis. It has been shown to play a role in the regulation of cell adhesion, cell migration, and the regulation of the cytoskeleton.

SPATA13 is also involved in the regulation of cellular processes that are important for the development and maintenance of the nervous system. It has been shown to play a role in the regulation of neurogenesis, the development of neural stem cells, and the regulation of synaptic plasticity.

SPATA13 is a potential drug target because of its involvement in the regulation of spermatogonial development, cellular processes that are important for tissue homeostasis, and the development and maintenance of the nervous system. It is also a good biomarker for the diagnosis of testicular cancer and other neurodegenerative diseases.

In conclusion, SPATA13 is a protein that is expressed in various tissues of the body and is involved in the regulation of spermatogonial development, cellular processes that are important for tissue homeostasis, and the development and maintenance of the nervous system. It is a potential drug target and a good biomarker for the diagnosis of testicular cancer and other neurodegenerative diseases. Further research is needed to fully understand the role of SPATA13 in these processes and to develop effective treatments.

Protein Name: Spermatogenesis Associated 13

Functions: Acts as guanine nucleotide exchange factor (GEF) for RHOA, RAC1 and CDC42 GTPases. Regulates cell migration and adhesion assembly and disassembly through a RAC1, PI3K, RHOA and AKT1-dependent mechanism. Increases both RAC1 and CDC42 activity, but decreases the amount of active RHOA. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Involved in tumor angiogenesis and may play a role in intestinal adenoma formation and tumor progression

The "SPATA13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATA13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets